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the epithelial-mesenchymal 
transition via lysyl oxidase-like 
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Specific protein 1 (SP1) is associated with aggressive behavior, invasive clinical phenotype and poor 
clinical outcomes in various cancers. We studied whether SP1 exerts its effect on invasiveness and 
promotion of the epithelial-mesenchymal transition (EMT) by regulating lysyl oxidase-like 2 (LOXL2) 
in pancreatic ductal adenocarcinoma (PDAC) cell lines. We showed that silencing of SP1 in MIA Paca-2 
cell significantly decreased cell invasion and migration. In MIA Paca-2 cells, silencing of SP1 induced a 
reduction of LOXL2 expression, whereas LOXL2 silencing did not lead to a decrease in the expression 
of SP1. Chromatin immunoprecipitation assay demonstrated the binding of SP1 to LOXL2 promoter. 
Wound healing and transmigration assays also showed that transfection of both SP1 and LOXL2 siRNA 
induced most significant decrease of cell invasion and migration compared to either SP1 or LOXL2-
only silenced cells. Finally, we investigated the prognostic value of SP1 in patients with PDAC and SP1/
LOX2 expression was examined by immunochemistry. Univariate and multivariate analyses showed 
that tumor differentiation and co-expression of SP1 and LOXL2 were independent factors for disease-
free survival. In summary, our study demonstrates that SP1 modulates EMT and is involved in tumor 
invasion and migration of PDAC cells through the regulation of LOXL2.
Pancreatic cancer is the 5th leading cause of cancer-related deaths in Korea and is among the most lethal of all 
malignancies1. Early local invasion and high recurrence rate contributes to the poor prognosis. Therefore, it is 
important to fully understand the mechanism of early invasion and epithelial-mesenchymal transition (EMT) in 
pancreatic cancer.
Specific Protein 1 (SP1), identified as a transcription factor for the simian virus 40 major immediate early 
gene2,3, is required for the transcription of housekeeping genes4. Importantly, high SP1 levels in various neoplasms 
are correlated with aggressive behavior, invasive clinical phenotypes, increase recurrence rates, and decreased sur-
vival5–8, and both SP1 and EMT markers levels are elevated in cancer cells9. Also in pancreatic cancer, Hang et al. 
recently reported that SP1 is involved in the angiogenesis and metastasis of pancreatic cancer by upregulating the 
expression of cyclooxygenase-28.
LOX-like 2 (LOXL2) is a member of the lysyl oxidase (LOX) family, responsible for the stabilization of colla-
gen and elastin fibers in extracellular matrix10. Especially, most studies in regards to oncogenic function of LOXL2 
have been reported in breast cancers. One research discovered the positive correlation between the onset of EMT 
and LOXL2 expression, which suggested LOXL2 contributes to the induction of EMT11. Likewise, upregulation 
of LOXL2 is associated with oncogenic stress response and tumorigenesis in pancreatic ductal adenocarcinoma 
(PDAC)12. Additionally, in pancreatic cell lines, LOXL2 activates EMT-like processes, which are associated with 
invasive and migratory properties13.
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SP1 has been indicated as one of the transcription factors involved in LOXL2 expression14. Therefore, here, we 
investigated the effect of SP1 on invasiveness and EMT in PDAC cells through LOXL2 regulation and evaluated 
the clinical impact of SP1 as a prognostic factor in patients with pancreatic cancer.
Figure 1. Expression of SP1 and EMT markers in PDAC cell lines. (A,B) Western blot analysis (A) and RT-PCR 
(B) relative to the expression of SP1 and EMT markers in the indicated cell lines. γ-tubulin (A) and β-actin (B) 
were used for normalization.
Figure 2. SP1 affects the expression of EMT markers in PDAC cell lines. (A) Western blotting and 
quantification using Image j program of the indicated proteins in MIA Paca-2 cells: silencing of SP1 (siSP1) 
reduced SP1, snail, and vimentin levels. (B) Western blotting and quantification using Imagej program of the 
indicated proteins in PANC-1 cells: siSP1 reduced SP1 and snail, and increased E-Cadherin. γ-tubulin was used 
for normalization. (C) Immunofluorescence assay to confirm the effect of siSP1 treatment on pancreatic cancer 
cell morphology. Both cell lines were transformed to epithelial cell shape after siSP1 treatment.
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Materials and Methods
Patients. A total of 84 consecutive patients who underwent R0 resection for PDAC from November 2002 to 
May 2012 at a single tertiary hospital were enrolled in this study. Twenty-two patients with incomplete medical 
records, lost to follow-up or without tissue samples were excluded, and the data of 62 patients were retrospectively 
reviewed. Patients were examined for follow-up every three months during the first year, and every six months 
afterwards. This study was approved by the Institutional Review Board of Gangnam Severance Hospital, Yonsei 
University, Seoul, Korea (3-2014-0153). Informed consent was obtained from all participants, and all methods 
were performed in accordance with the relevant guidelines and regulations.
Immunohistochemical (IHC) Staining. An anti-SP1 antibody (Thermo Fisher Scientific, Cleveland, OH, 
USA) and an anti-LOXL2 antibody (Abcam, Cambridge, UK) were used to detect the SP1 and LOXL2. ICH 
staining procedures and intensity categorization have been described in our previous report13. Two pathologists 
without any information of the enrolled patients were participated in the interpretation of IHC.
Figure 3. Knockdown of SP1 inhibits the invasion and migration of PDAC cells. (A) Transmigration assay in 
MIA Paca-2 cells transfected with control or SP1 siRNAs: SP1 knockdown significantly inhibits cell invasion. 
(B) Wound healing assay in MIA Paca-2 cells transfected with control or SP1 siRNAs: SP1 knockdown 
significantly decreased cell migration 24 hours after removal of the insert (see Materials and Methods for 
details). (C) Proliferation assay to compare cell growth rates among control, negative control, transfection 
reagent and siSP1 treatment groups. There was no significant difference in absorption at 450 nm among the 
groups.
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Cell culture. We used human PDAC cell lines (MIA Paca-2, PANC-1, AsPC-1, and BxPC-3) obtained from 
the American Type Culture Collection (ATCC; Manassas, VA, USA), and cells were grown according to the 
ATCC recommendations.
SP1 RNA interference. For knockdown of gene expression, the following small interfering RNA (siRNA) 
were purchased from Bioneer (Daejeon, Korea): siSP1 (sense: 5′–CA GAUACCAGACCUCUUCU-3′, antisense: 
5′-AGAAGAGGUCUGGUAUC UG-3′), siLOXL2 (sense: 5′-CAGUCUAUUAUAGUCACAU-3′, antisense: 
5′-AUGUGACUAUAAUAGACUG-3′). Transfection was carried out using TransIT® -LT1 (Mirus Bio, Madinon, 
Wi, USA) or Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturers’ instructions. 
Cells were harvested and processed 48–72 hours post-transfection.
Reverse transcription polymerase chain reaction (RT-PCR). RNA was extracted using TRIzol 
(Invitrogen), and purified using an RNA extraction kit (Easy-Spin Total RNA extraction kit, Intron, Korea). For 
RT- PCR, we used a one-step RT-PCR kit (Intron) and a GeneAmp PCR System 9700 (Appied Biosystems, Foster 
City, CA, USA) according to the manufacturers’ instructions.
The primers used for RT PCR were SP1 (F: 5′-CCATACCCCTTAACCCCG-3′, and R: 5′-GAATTTTCACTAA 
TGTTTCCCACC-3′). The primers of LOXL, Snail, CDH1, L1CAM, and GAPDH were same as our previous 
report13.
Western blot analysis. The procedure of Western blot analysis was described in our previous report13.
Wound healing assay. For wound healing assays, we used 24-well culture inserts (ibidi, Martinsried, 
Germany). Cells were transfected and, 24 hours after, were counted: 70 μL of a cell suspension at 3 × 105 cells/mL 
was seeded on each side of the insert. After 24 hours, the insert was removed to create a wound, and 0.5 mL of 
growth medium was added. The cells were washed three times with phosphate-buffered saline and incubated for 
24 hours. The wounds were then visualized under a microscope (Axio Observer Z1, Zeiss, Jena, Germany).
Transmigration assay. For the transmigration assays, the upper side of 8.0-μm Transwell® inserts (Corning 
Costar, NY, USA) was coated with Matrigel (BD Bioscience). After transfection, 1 × 105 of MIA Paca-2 cells were 
re-suspended in serum-free medium and seeded on the upper chambers. The lower chambers were filled with 
growth medium. After 24 hours, the cells on the lower surface of the membrane were stained using a Diff-Quick 
staining kit (Sysmex, Kobe, Japan), and counted under an inverted microscope. Values are expressed as mean cell 
numbers in five random fields of view (200×).
Figure 4. SP1 regulates the expression of EMT-related factor LOXL2. (A) LOXL2 expression in PDAC cell lines. 
(B) Western blot analysis after silencing LOXL2 or SP1 in MIA Paca-2 cells: SP1 silencing induced a reduction 
of LOXL-2 expression, whereas LOXL-2 silencing did not decrease the expression of SP1. (C) ChIP assay. The 
scheme indicates LOXL2 promoter and the regions recognized by the primers used in the qPCR assays. These 
assays show that SP1 binds to the P1 region of LOXL2 promoter.
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Cell proliferation assay. Cells were seeded in a 96-well plate at a 1 × 103 cells/well, 24 hours before the 
siRNA transfection. siRNA was transfected by following the manufacturers’ instructions. After 48 hour incu-
bation, medium was replaced to fresh medium in a final volume of 100 μl/well. 10 μl of WST (Ez-cytox, Dogen, 
Korea) was added to each well and incubated for 1 hours. The absorbance of each well was measured at 450 nm 
using a microplate reader.
Immunofluorescence assay. MIA Paca-2 and PANC-1 cells were grown on 4 well chamber slides. The cells 
were washed three times with PBS after SP1 siRNA treatment, and then fixed in 4% paraformaldehyde for 15 min 
and permeabilized with 0.1% Triton ×100 (Sigma) for 10 min. After three time washing with PBS, incubate cells 
with 1% BSA in PBST (PBS + 0.1% Tween20) for 30 min. Polyclonal rabbit antibodies against human SP1 (1:200, 
Abcam, Cambridge, UK), F-actin (1:200, Abcam, Cambridge, UK) were applied overnight at 4 °C. Washed cells 
were incubated with Secondary Alexa Fluor 555 anti-rabbit IgG (1:1000, Cell signaling) and Alexa Fluor 488 
anti-mouse IgG (1:1000, Cell signaling) for 1 hour at room temperature, washed again. Cells were mounted in 
DAPI Staining Solution (Abcam, Cambridge, UK), and analyzed using confocal microscopy (LSM510, Carl Zeiss, 
Jena Germany).
Chromatin Immunoprecipitation(ChIP). ChIP assays were performed with the EpiTect ChIP Oneday 
kit (QIAGEN, Hilden, Germany) following the manufacturer’s instructions. A total of 5 × 106 MIA Paca-2 cells 
were cross-linked with 1% formaldehyde at room temperature for 10 min. Sonication was performed on ice to get 
200 to 1,000 bp DNA fragments. Chromatin was pre-cleared with anti-IgG antibody (Santa Cruz Biotechnology) 
and immunoprecipitated with an anti-SP1 antibody. After reverse cross-linking and DNA isolation and purifica-
tion, DNA from input (diluted 1:100) or immunoprecipitated samples were assayed by quantitative PCR (qPCR), 
performed on a LightCycler®480 Real-Time PCR system (Roche, Diagnostics, Mannheim, Germany) using the 
SYBT Green I Mastermix (Applied Biosystems). The products were then separated by 2% agarose gel electro-
phoresis. The following primers were used: P1 (−898 to −778, F: 5′-CAACCCTGACCCCAGCCTCT-3′, and R: 
5′-GCAAGGAAAGAGAC ACAGCA-3′), P2 (−878 to −758, F: 5′-GTCCTTTACTCCACAGATAGAT GGGT-3′, 
and R: 5′-GGGACAACTATTTGGCTGCAG-3′), P3 (−759 to −639, F: 5′-CTGCGCCAAATAGTTGTCCC-3′, 
and R: 5′-AGCAGGGCTTAGAG AGAAACG-3′), P4 (−568 to 448, F: 5′-GGACATCTGGGGGTCCTCT-3′, and 
R: 5′-GCGGATTTTGCATTTCACTCCA-3′), P5 (−210 to 90, F: 5′-GTTGC CCAGAGCTCACTG-3′, and R: 
5′-GGTTACCCTACTGGCCTGG-3′).
Figure 5. The effect of SP1 and LOXL2 silencing on EMT. (A,B) Western blotting and quantification using 
Image j program in MIA Paca-2 and PANC-1; silencing of SP1 and LOXL2 induced a remarkable decrease of 
EMT markers as well as silencing of LOXL2 alone.
6Scientific RepoRts |          (2019) 9:5933  | https://doi.org/10.1038/s41598-019-42501-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Statistical analysis. All statistical analyses were performed using the SPSS software, version 21.0 (SPSS Inc., 
Chicago, IL, USA). Categorical variables were evaluated using the chi-square or the Fisher’s exact tests, and continu-
ous variables were analyzed using the Student’s t-test. Survival curves were plotted using the Kaplan-Meier method, 
and differences in survival time among groups were assessed with the log-rank test. Disease-free survival (DFS) was 
measured from the date of surgery to the date of recurrence or last follow-up. Univariate and multivariate analyses 
using the Cox proportional hazards regression method were performed. A P-value < 0.05 was considered significant.
Results
Expression of SP1 in human PDAC cell lines. Western blotting and RT-PCR were performed in four dif-
ferent PDAC cell lines: MIA Paca-2, PANC-1, AsPC-1, and BxPC-3 cell lines. SP1 was expressed in common at all 
cell lines, whereas epithelial (E-cadherin) and mesenchymal (Snail, Vimentin, N-cadherin) markers showed var-
ying levels of expression (Fig. 1). MIA Paca-2 and PANC-1 cells had relatively stronger mRNA expression of Snail 
compared to other cell lines, and MIA Paca-2 showed no expression of N-cadherin. These results were consistent 
with previous researches15–17, which demonstrated heterogenous expression of EMT markers as a reflection of 
own aggressive and metastatic behavior of each cell line.
Correlation between SP1 expression and EMT markers in PDAC. To evaluate the effect of SP1 on 
the expression of EMT markers, we generated MIA Paca-2 and PANC-1 cells in which SP1 had been silenced. 
SP1-silenced cells exhibited significant reduction in the expression of Snail, important for EMT. Additionally, in 
Paca-2-siSP1, the expression of Vimentin was reduced, and in PANC-1-siSP1, the expression of E-cadherin was 
Figure 6. SP1 regulates EMT of PDAC cells through LOXL2. (A) Transmigration assay in MIA Paca-2; 
transfection of both SP1/LOXL2 siRNA induced the most significant decrease of cell invasion compared to SP1-
only silenced cells. (B) Wound healing assay in MIA Paca-2; transfection of both SP1/LOXL2 siRNA decreased 
cell migration more than transfection of SPI siRNA. (C) Proliferation assay to compare cell growth rates among 
control, negative control, transfection reagent and siSP1 treatment groups. There was no significant difference in 
absorption at 450 nm among the groups.
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increased (Fig. 2A,B). We also performed immunofluorescence assay to show the morphological changes after siSP1 
treatment. After siSP1 treatment, both cell lines were transformed to epithelial cell shape with exhibiting the cortical 
actin architecture, and this tendency was more prominent in PANC-1 cells compared to MIA Paca-2 cells (Fig. 2C).
Effects of SP1 expression on cell invasion and migration. In transmigration assays, SP1-silenced 
MIA Paca-2 cells showed a statistically significant decrease of cell invasion (Fig. 3A). Moreover, in wound heal-
ing assays, SP1 silencing significantly decreased cell migration compared to control cells (Fig. 3B). On the other 
hands, the proliferation assay showed no significant cell growth after siSP1 treatment compared to negative con-
trols (Fig. 3C).
EMT regulation by SP1-LOXL2 axis. Higher LOXL2 expression is associated with the invasiveness of 
PDAC and the lower survival rate of patients. As demonstrated in Fig. 4A, LOXL-2 was detected in MIA Paca-2 
and PANC-1 cells, in agreement with our previous study4. In MIA Paca-2, SP1 silencing induced a reduction of 
LOXL-2 expression, whereas LOXL-2 silencing did not affect SP1 levels (Fig. 4B). Additionally, to confirm the 
transcriptional regulation of LOXL2 by SP1, ChIP assay with qPCR was performed. We identified the promoter 
region of LOXL2 containing one of the predicted SP1 binding sites described in a recent research by Jourdan-Le 
Saux C et al.14 (Fig. 4C). Corresponding to ChIP assay, the agarose gel electrophoresis also demonstrated SP1 
binding18 to P1 site.
To investigate how SP1 regulates EMT through LOXL2, we performed additional silencing experiments. In 
MIA Paca-2 and PANC-1 cells, silencing of both factors induced a remarkable decrease of EMT marker levels, 
higher than that obtained upon silencing of either SP1 or LOXL2 (Fig. 5A,B). Additionally, transmigration and 
wound healing assays showed the greatest decline in cell migration when both factors were silenced (Fig. 6A,B). 
Again, the proliferation assay showed no significant cell growth after siSP1 treatment compared to negative con-
trols (Fig. 6C).
Figure 7. Expression of SP1 in human tissues. (A) Immunohistochemistry of SP1 in normal and cancer tissue. 
(B) Western blot analysis of SP1 protein expression in normal and tumor tissues (N = 5). The graph indicates 
the quantification of the results. (C) RT-PCR analysis of SP1 mRNA expression in normal and tumor tissues 
(N = 5). The graph indicates the quantification of the results.
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SP1 and LOXL2 expression in human PDAC samples. Next, we investigated SP1 and LOXL2 
expression in PDAC samples from 62 patients. As described in Fig. 7, in PDAC tissue, the overexpression of 
SP1 was observed, whereas the normal pancreatic tissue did not express SP1 by IHC staining, western blotting 
and RT-PCR. Patient characteristics according to the expression of SP1/LOXL2 evaluated by IHC staining are 
described in Table 1. There was no significant difference in cell differentiation, tumor size, invasion depth or 
lymph node metastases among patient groups divided according to the expression of SP1/LOXL2.
However, multivariate analyses indicated that tumor differentiation and high expression of both SP1 and 
LOXL2 were independent poor prognostic factors for DFS (Table 2). Additionally, Kaplan Meier survival analyses 
showed that the patients with high expression of both SP1 and LOXL2 had lower DFS compared to other groups 
with clinical significance (Fig. 8).
Discussion
PDAC is characterized by extensive stromal and matrix deposition (demoplasia), which generates high levels of 
stress in the tumors and compression of the vasculature, and promotes a hypoxic, nutrient-poor environments18. 
These conditions cause endoplasmic reticulum(ER) stress, which, in turn, initiates the unfolded or incorrectly 
folded protein response19–21.
SP1 is a highly regulated transcription factor that plays a critical role for the regulation of genes involved in 
cancer progression22. Earlier studies have demonstrated SP1 overexpression in various cancers including sarcoma, 
and adenocarcinomas in colon or stomach5–7,23–25, whereas minimal or no expression of SP1 was detected in normal 
Figure 8. Disease-free survival analyses according to the expression of SP1 and LOXL2. (A,B) 5-year DFS 
curves according to the expression of SP1 or LOXL2: no significant differences were found according to the 
expression of SP1 or LOXL2. (C) 5-year DFS curves according to the co-expression of two factors: there was no 
significant difference in 5-year DFS rates among the four indicated groups. (D) 5-year DFS curves according 
to the expression of both SP1 and LOXL2 in the SP1(+)/LOXL2(+) vs. the SP1(−)/LOXL2(−), SP1(−)/
LOXL2(+), and SP1(+)/LOXL2(−) groups. The group with SP1(+)/LOXL2(+) showed significantly lower DFS 
compared to all others.
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Factors N = 62
SP1 LOXL2
Negative 
(n = 38)
Positive 
(n = 24) P
Negative 
(n = 14)
Positive 
(n = 48) P
Sex 0.434 0.368
Male 28 19 (50.0%) 9 (37.5%) 8 (57.1%) 20 (41.7%)
Female 34 19 (50.0%) 15 (62.5%) 6 (42.9%) 28 (58.3%)
Age 0.311 0.7
≤60 11 5 (13.2%) 6 (25.0%) 3 (21.4%) 8 (16.7%)
>60 51 33 (86.8%) 18 (75.0%) 11 (78.6%) 40 (83.3%)
Operations 1 0.315
PD 44 27 (71.1%) 17 (70.8%) 8 (57.1%) 36 (75.0%)
Others 15 11 (28.9%) 7 (29.2%) 6 (42.9%) 12 (25.0%)
Differentiation 0.505 1
Well 11 8 (21.1%) 3 (12.5%) 2 (14.3%) 9 (18.8%)
Mod. to Poor 51 30 (78.9%) 21 (87.5%) 12 (85.7%) 39 (81.3%)
Tumor size (mean ± SD, cm) 3.20 ± 1.32 3.18 ± 1.36 0.955 3.26 ± 1.03 3.16 ± 1.40 0.805
Invasion depth 0.736 1
T1/2 51 32 (84.2%) 19 (79.2%) 12 (85.7%) 39 (81.3%)
T3/4 11 6 (15.8%) 5 (20.8%) 2 (14.3%) 9 (18.8%)
LN metastasis 1 0.519
Negative 19 12 (31.6%) 7 (29.2%) 3 (21.4%) 16 (33.3%)
Positive 43 26 (68.4%) 17 (70.8%) 11 (78.6%) 32 (66.7%)
PNI 0.764 1
Negative 15 10 (26.3%) 5 (20.8%) 3 (21.4%) 12 (25.0%)
Positive 47 28 (73.7%) 19 (79.2%) 11 (78.6%) 36 (75.0%)
LVI 0.434 1
Negative 31 21 (55.3%) 10 (41.7%) 7 (50.0%) 24 (50.0%)
Positive 31 17 (44.7%) 14 (58.3%) 7 (50.0%) 24 (50.0%)
Table 1. Patient characteristics according to the expression of SP1 and LOXL2. Abbreviation: N, number; PD, 
pancreaticoduodenectomy; Mod., moderate; LN, lymph node; PNI, perineural invasion; LVI, lymphovascular 
invasion.
Factors N
DFS Univariate analysis Multivariate analysis
median (range) HR 95% CI P HR 95% CI P
Differentiation
Well 11 16.1 (5.8–87.4) 1 1.365–6.817 0.007 1 1.528–7.899 0.003
Mod. to Poor 51 8.3 (1.1–71.4) 3.05 3.474
Invasion depth
T1/2 51 10.3 (1.1–87.4) 1 0.653–2.592 0.455
T3/4 11 11.8 (3.5–69.7) 1.301
LN metastasis
Negative 19 8.3 (1.1–69.5) 1 0.483–1.512 0.59
Positive 43 11.0 (1.5–87.4) 0.855
PNI
Negative 15 11.3 (1.1–71.4) 1 0.501–1.741 0.83
Positive 47 9.2 (3.5–87.4) 1.071
LVI
Negative 31 12.7 (1.1–69.7) 1 0.610–1.749 0.903
Positive 31 9.4 (1.5–87.4) 1.033
SP1 status
Negative 38 12.7 (1.1–87.4) 1 0.742–2.176 0.384
Positive 24 8.1 (1.5–69.7) 1.27
LOXL2 status
Negative 14 13.2 (7.0–71.4) 1 0.799–2.875 0.203
Positive 48 8.3 (1.1–87.4) 1.516
SP1/LOXL2 status
All others 45 12.7 (1.1–87.4) 1 1.001–3.244 0.039 1 1.170–3.953 0.014
SP1(+)/LOXL2(+) 17 7.1 (1.5–56.0) 1.802 2.151
Table 2. Univariate and multivariate analyses of the relationship between DFS and clinicopathologic variables 
by Cox regression hazard model. Abbreviation: N, number; DFS, disease-free survival; Mod., moderate; LN, 
lymph node; PNI, perineural invasion; LVI, lymphovascular invasion.
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differentiated cells. Similarly, SP1 is overexpressed in pancreatic cancer8,9,19. It has been reported that downregula-
tion of SP1 interferes with recovery from ER stress, and activation of unfolded protein response in PDAC19.
On the other hand, the overexpression of LOXL2 in PDAC cells induces EMT, cell migration and invasion13. 
Additionally, LOXL2 is one of the most specifically and highly expressed genes in pancreatic cancer. Therefore, 
several groups have investigated the mechanisms that cause LOXL2 upregulation. One recent study reported that 
the promoter of LOXL2 contains binding sites for several transcription factors including SP114. In this study, we 
found that SP1 binds to LOXL2 promoter and regulates the expression of EMT markers.
Our clinical data demonstrated that the overexpression of SP1 and LOXL2 correlates with poor prognosis in 
patients with pancreatic cancer. However, the overexpression of either SP1 or LOXL2 did not significantly corre-
late with poor clinical outcomes including lymph node metastasis, depth of invasion, or lymphovascular invasion. 
These unexpected results might be driven from the basic issue that SP1 regulates the expression of heterogenous 
target proteins9. Therefore, the signaling pathway through SP1-LOXL2 axis is not the only one contributing to 
tumor invasion and progression in pancreatic cancer.
Moreover, as only tumor core tissue was used in the experiments, this study did not reflect the characteristics 
of tumor microenvironment. Kasashima et al.26 demonstrated that LOXL2 expression in stromal cells, not in 
cancer cells, was associated with poor prognosis in gastric cancer. Considering the nature of pancreatic cancer 
that produces favorable microenvironment for cancer progression, further additional experiments using tumor 
stroma or invasion border should have been performed. However, in this study, we could not perform experi-
ments using tumor stroma or invasion border owing to the lack of tissue sample.
Nevertheless, this study indicates that SP1 may serve as a therapeutic target for selected patients with pancre-
atic cancer, especially if silenced together with LOXL2. However, additional studies of SP1 function and mecha-
nism of action are required prior to practical use of SP1 for pancreatic cancer treatment.
Conclusion
Our study demonstrated that SP1 modulates EMT and is involved in invasion and migration of PDAC cells by 
regulating LOXL2. In clinical data, the co-overexpression of SP1 and LOXL2 significantly correlates with poor 
prognosis in patients with pancreatic cancer.
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